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Short Treatment and the WHO Pneumonia - What are We
Treating?
Z. Bhutta
The Aga Khan University, Karachi, Pakistan
It is estimated that there are 5-9 episodes of acute respi-
ratory infections (ARI) per year / under 5 children, the vast
majority of which are viral. Some 2-3% of these episodes
represent pneumonia and between 7-13% (some 11-17 mil-
lion acute lower respiratory infections are severe enough to
require hospital admission.
Despite numerous advances in understanding the burden
and epidemiology of childhood respiratory pneumonia, the
disorder still accounts for almost 1.8 million child deaths
annually, 98% in developing countries. It is widely stated
that in developing countries, most pneumonia is bacterial
and most acute respiratory infection related deaths are due
to pneumonia, however, the exact proportion of these infec-
tions which are related to viral or bacterial infections is
unclear. Given the high burden of deaths in young children,
WHO has progressively developed algorithms for the diag-
nosis and management of acute respiratory infections based
on clinical criteria of fast breathing and chest indrawing.
These criteria have been used for the diagnosis and therapy
of pneumonia in a range of settings. In recent years, the suc-
cess of short course antibiotic therapy of such episodes has
opened the possibility of improving community case man-
agement of such infections and reducing rates of resistance.
However, a legitimate question has been raised as to the
nature of acute respiratory infections diagnosed by the WHO
algorithms. This presentation will review the current state
of knowledge in relation to the etiology and outcomes of res-
piratory infections in children in developing countries and
also discuss the implications for research and programs.
Our ﬁndings indicate that the current criteria for deﬁning
pneumonia as suggested by WHO are too broad and proba-
bly include a host of conditions, including viral infections
and asthma, which do not require antibiotics. A much more
effective and validated deﬁnition and clinical description of
pneumonia is needed for programmatic settings.
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Can Short Antibiotic Treatment be Widely Used in Devel-
oped Countries
R. Dagan
Beer Sheva University, Beer-Sheva, Israel
Childhood pneumonia is the most common killer of
children <5 years worldwide. Although in the developed
world pneumonia does not commonly result in death, it
is an extremely common disease. Treatment is almost
universally with antibiotics. However, the lack of appro-
priate deﬁnition of pneumonia, the difﬁculty in diagnosing
the pathogen and cultural differences make it extremely
difﬁcult to agree on the ideal treatment. A short antibi-
otic course is preferred to a longer one, since if equally
effective, it should be associated with lower cost, less
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dverse events and lower rates of antibiotic resistance
n the community. An extensive literature search using
combination of the words ‘‘pneumonia’’, ‘‘community-
cquired’’, ‘‘treatment’’, ‘‘drug’’, ‘‘antibiotic’’, short’’,
‘shortened’’, ‘‘day (s)’’, and ‘‘child’’ resulted in a few
rticles only dealing with short duration treatment of pneu-
onia in children, all in the developing world and most
ealing with pneumonia deﬁned by the WHO criteria (used
n locations where no modern medicine can be applied). We
ndertook a prospective, double blind, randomized study,
omparing high-dose amoxicillin (80mg/kg) administered
or 5 vs. 10 days in children with community-acquired alve-
lar pneumonia with the following inclusion criteria: 1) <5
ears old; 2) radiologically proven alveolar pneumonia; 3)
emperature ‘‘38.5 ◦C; 4) peripheral WBC’’ 15,000/mm3.
e followed the children both clinically and with labora-
ory ﬁndings for a month. The study will be unblinded after
anuary 31st and the preliminary results will be presented.
In conclusion: Paucity of data and difﬁculty in deﬁning
hildhood pneumonia in the developed world result in confu-
ion in regard to short treatment. However, the ﬁrst studies
ill reveal, at least in some deﬁned subgroups of pneu-
onia, the efﬁcacy and the potential use of short-course
reatment in childhood pneumonia.
oi:10.1016/j.ijid.2010.02.1556
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entation)
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linico epidemiologic and molecular characterization of
etallo beta lactamases (MBLs) producing nosocomial
seudomonas aeruginosa (PSA)
. Chatterjee1,∗, A. Kumar2, K.N. Prasad3, D. Mathai1, A.
anoharan1
Christian Medical College and Hospital, Vellore, Tamil
adu, India
Amrita Institute of Medical Science, Kochi, India
Sanjay Gandhi Post Graduate Institute of Medical Sciences,
ucknow, India
Background: The high prevalence of co-resistance to
etalactam, aminoglycoside and quinolone against PSA has
ecessitated increased use of carbapenems. MBL production
mong PSA is one of the several mechanisms causing car-
apenem resistance (CARB-R) transferable by integrons. We
urveyed MBL production among PSA isolates collected via
ulticentric surveillance study.
Methods: During March-September 2009 BMPLIII received
5 consecutively collected PSA causing infections of (skin
nd soft tissue-48, blood and respiratory tract 11 each,
nd other sites, 5) from four (50-AIMS,Kochi, 21-SGPGIMS,
-MGIMS,2-AIIMS,Delhi) Indian Medical centers. Antimicro-
ial susceptibility testing by Kirby Bauer method against
eftazidime (CZD), cefepime(FEP), piperacillin/tazobactam
TZP), ticarcillin /clavulanic acid (TIM), gentamicin
GEN), amikacin(AK), ciproﬂoxacin(CIP), imipenem(IMP),
eropenem(MEM), aztreonam(ATM) and colistin(CL) was
one. MBL was screened by the Combined Disk Diffusion Test
CDDT) method using 0.5 M EDTA (930g) as the inhibitor
